Payment overview · 2025
General Payments
$197.70
8 reported records · 6 companies
Healthcare provider profile · identity verified
Nathan A Gray, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KNOXVILLE, TN · NPI 1952347999
Verified facts
What the public records show
CMS Open Payments records show Nathan A Gray, MD received $197.70 in general payments during 2025 across 8 reported records.
HEARTFLOW, INC. accounted for 43.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Shingrix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $85.87 | 43.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.75 | 15.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $28.85 | 14.6% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $21.01 | 10.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.43 | 8.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.79 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $197.70 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $85.87 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.75 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $28.85 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 22 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
22 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 322 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 231 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 213 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 62 |
| Metformin Hcl | Metformin Hcl | 163 | 46 |
| Losartan Potassium | Losartan Potassium | 152 | 44 |
| Omeprazole | Omeprazole | 146 | 42 |
| Simvastatin | Simvastatin | 107 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 20 |
| Synthroid | Levothyroxine Sodium | 86 | 22 |
| Lisinopril | Lisinopril | 85 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 85 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 25 |
| Meloxicam | Meloxicam | 69 | 21 |
| Sertraline Hcl | Sertraline Hcl | 68 | 16 |
| Montelukast Sodium | Montelukast Sodium | 66 | 18 |
| Trazodone Hcl | Trazodone Hcl | 63 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 14 |
| Finasteride | Finasteride | 61 | 15 |
| Ezetimibe | Ezetimibe | 60 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 18 |
| Lovastatin | Lovastatin | 55 | 17 |
| Gabapentin | Gabapentin | 54 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Allopurinol | Allopurinol | 45 | 13 |
| Carvedilol | Carvedilol | 43 | 12 |
| Glimepiride | Glimepiride | 41 | 12 |
| Potassium Chloride | Potassium Chloride | 41 | 13 |
| Bupropion Xl | Bupropion Hcl | 39 | 14 |
| Eliquis | Apixaban | 37 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 33 | 33 |
| Benazepril Hcl | Benazepril Hcl | 32 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 12 |
| Valsartan | Valsartan | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 12 |
| Ozempic | Semaglutide | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Furosemide | Furosemide | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | 11 |
| Celecoxib | Celecoxib | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Prednisone | Prednisone | 14 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Topiramate | Topiramate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $197.70 · 8 records | HEARTFLOW, INC. | AREXVY, FFRct, FREESTYLE LIBRE 3, NEFFY, OTEZLA, REPATHA, SHINGRIX, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error